dose optimization trial

Top Biotechnology Stock Picking: Genocea Biosciences, Inc. (GNCA), Baxalta …
www.zergwatch.com

Genocea Biosciences, Inc. (GNCA) on March 31, 2016 announced positive 12 month efficacy data from its Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. GEN-003 demonstrated sustained and statistically significant …

9
Like
Save
Genital herpes treatment: Genocea Biosciences announce data from Phase II trials
outbreaknewstoday.com

Cambridge, Mass. biopharmaceutical company, Genocea Biosciences, Inc., announced this week positive 12 month efficacy data from its Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. GEN-003 demonstrated …

3
Like
Save
Genocea Reports Third Quarter 2015 Financial Results
www.businesswire.com

On October 7, 2015, Genocea reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best …

3
Like
Save
Today's Watch List: General Motors Company (NYSE:GM), Genocea Biosciences, Inc …
www.benchmarkmonitor.com

… Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

4
Like
Save
Moving Stocks: Intermolecular, Inc. (NASDAQ:IMI), Emerson Electric Co. (NYSE …
www.benchmarkmonitor.com

Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

9
Like
Save
Top Stories: Nivalis Therapeutics, Inc. (NASDAQ:NVLS), Itau Unibanco Holding …
www.stocktranscript.com

… Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

6
Like
Save
Noteworthy Biotech Stocks to Watch for – Genocea Biosciences Inc (NASDAQ:GNCA …
investorwired.com

… T cell-directed vaccines and immunotherapies, reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

6
Like
Save
Noteworthy Biotech Stocks to Watch for – Genocea Biosciences Inc (NASDAQ:GNCA …
investorwired.com

… T cell-directed vaccines and immunotherapies, reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

4
Like
Save
Biotech Stocks With Optimistic Trend – Genocea Biosciences Inc (NASDAQ:GNCA …
www.wsobserver.com

The company, on October 7, 2015, declaredpositive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best …

4
Like
Save
Three Highly Unusual Volume Increases: Genocea Biosciences Inc (NASDAQ:GNCA …
www.wallstreetpoint.com

The Healthcare Company on October 7, 2015statedpositive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its …

8
Like
Save